

ASX Release

Top 20 Shareholders

PERTH, AUSTRALIA – 1 March 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), hereby provides an update of the top 20 shareholders at 27 February 2019.

Rank	Holder Name	Number of shares	% Held
1	KAMALA HOLDINGS PTY LTD	82,300,000	3.19
2	SCINTILLA STRATEGIC INVESTMENTS LIMITED	50,000,000	1.94
3	ZERRIN INVESTMENTS PTY LTD	49,828,883	1.93
4	MR THOMAS MCGELLIN + MS TANYA KARAL	48,814,323	1.89
5	BAMBER INVESTMENTS PTY LTD	42,946,552	1.66
6	MR STEVE JOHN WICKS	32,553,239	1.26
7	CHELSEA INVESTMENTS (WA) PTY LTD	31,820,698	1.23
8	MR JAMES BRADLEY RICHARDSON	30,145,086	1.17
9=	ONICAS INVESTMENTS PTY LTD	30,000,000	1.16
9=	MR PETER NORMAN DUNN	30,000,000	1.16
11	J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	27,786,952	1.08
12	MR MARK ANDREW DUNCAN-SMITH	27,287,573	1.06
13	BANLAN PTY LTD	26,627,469	1.03
14	TADEA PTY LTD	26,056,000	1.01
15	MS GIOVANNA LINA GAN	25,000,000	0.97
16	BILL BROOKS PTY LTD	22,181,261	0.86
17	MR RICHARD STANFORD PARRY	21,533,333	0.83
18	WERINGA NOMINEES PTY LTD	21,150,000	0.82
19	UBS NOMINEES PTY LTD	20,931,820	0.81
20	PETO PTY LTD	20,880,000	0.81
Total		667,843,189	25.87



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER/MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
 Tel: +61 8 6142 5555
sjcarter@sudapharma.com

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer.

For more information, visit www.sudapharma.com